clinical trial · NCT05878561
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
Boryung Pharmaceutical Co., Ltd·phase3·completed·n = 248
Essential HypertensionFimasartan + IndapamideFimasartan + Indapamide placebo
brief summary
The objective of this clinical trial is to evaluate the efficacy and safety of BR1015 Combination therapy group in comparison with Fimasartan monotherapy group at Week 8 for essential hypertension patients who do not adequately responded by Fimasartan 30 mg
started
Nov 9, 2022
primary completion
Dec 2, 2024
completion
Dec 2, 2024
last updated
Dec 20, 2024
official title
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Adequately Responded by Fimasartan 30 mg
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol